CD4 and neoplasm: Further, TISCs have been shown to exert immune privilege, due to which, during the elimination phase of tumor immune editing, they are protected from cell death, allowing them to survive until the immune-escape phase, during which they will replicate and differentiate into cancer cells along with recruiting immunosuppressive cells such as MDSCs and FoxP3+ regulatory CD4+T cells (Tregs) [22,23,24].